HomeCompareIMAB vs STAG

IMAB vs STAG: Dividend Comparison 2026

IMAB yields 69.44% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMAB wins by $15.8K in total portfolio value
10 years
IMAB
IMAB
● Live price
69.44%
Share price
$2.88
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$11.77
Full IMAB calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — IMAB vs STAG

📍 IMAB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMABSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMAB + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMAB pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMAB
Annual income on $10K today (after 15% tax)
$5,902.78/yr
After 10yr DRIP, annual income (after tax)
$10.00/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, STAG beats the other by $382.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMAB + STAG for your $10,000?

IMAB: 50%STAG: 50%
100% STAG50/50100% IMAB
Portfolio after 10yr
$26.2K
Annual income
$237.00/yr
Blended yield
0.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

IMAB
Analyst Ratings
5
Buy
Consensus: Buy
Price Target
$8.00
+177.8% upside vs current
Range: $7.00 — $9.00
Altman Z
89.4
Piotroski
3/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMAB buys
0
STAG buys
0
No recent congressional trades found for IMAB or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMABSTAG
Forward yield69.44%3.44%
Annual dividend / share$2.00$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0.3%
Portfolio after 10y$34.2K$18.3K
Annual income after 10y$11.77$462.22
Total dividends collected$8.5K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$8.00$45.00

Year-by-year: IMAB vs STAG ($10,000, DRIP)

YearIMAB PortfolioIMAB Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$14,172$3,472.22$10,665$345.09+$3.5KIMAB
2$17,464$2,299.49$11,364$357.70+$6.1KIMAB
3$20,010$1,324.09$12,098$370.43+$7.9KIMAB
4$22,120$708.96$12,869$383.28+$9.3KIMAB
5$24,035$366.22$13,677$396.23+$10.4KIMAB
6$25,903$185.94$14,524$409.27+$11.4KIMAB
7$27,810$93.64$15,411$422.41+$12.4KIMAB
8$29,804$46.98$16,339$435.61+$13.5KIMAB
9$31,913$23.53$17,311$448.89+$14.6KIMAB
10$34,159$11.77$18,327$462.22+$15.8KIMAB

IMAB vs STAG: Complete Analysis 2026

IMABStock

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Full IMAB Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this IMAB vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMAB vs SCHDIMAB vs JEPIIMAB vs OIMAB vs KOIMAB vs MAINIMAB vs PLDIMAB vs EQRIMAB vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.